+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dyskinesia Market - Global Forecast 2026-2032- Product Image
Dyskinesia Market - Global Forecast 2026-2032- Product Image
Sale

Dyskinesia Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082614
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dyskinesia Market is projected to reach USD 3.93 Billion in 2026. It is expected to continue growing at a CAGR of 7.55%, reaching USD 6.10 Billion by 2032.

Dyskinesia: Executive Summary and Market Context

Dyskinesia refers to involuntary, irregular, and often repetitive movements that may arise from neurological disorders, medication exposure, or other clinical conditions. Its presentation can range from mild motor fluctuations to movements that impair mobility, communication, daily activities, and quality of life. Clinical management commonly requires assessment of symptom patterns, treatment history, functional impact, and coexisting conditions.

Care Is Shifting Toward Earlier Recognition and Individualized Management

The dyskinesia landscape is being reshaped by greater emphasis on early recognition, structured movement assessment, and treatment plans tailored to the individual. Clinicians increasingly combine medication review, rehabilitation, caregiver education, and specialist consultation rather than relying on a single intervention. This shift also places greater importance on longitudinal monitoring because symptoms can vary across the day and change as underlying disease or treatment exposure evolves.

Artificial Intelligence Is Strengthening Monitoring, Documentation, and Decision Support

Artificial intelligence can support dyskinesia care by analyzing video, wearable-sensor, and patient-reported data to identify movement patterns that may be difficult to capture during a brief clinical visit. Potential applications include automated symptom documentation, remote monitoring, therapy-response tracking, and decision support. These tools require clinical validation, representative datasets, privacy safeguards, explainable outputs, and workflows that preserve clinician oversight; they should complement rather than replace neurological assessment.

Regional Insights: Uneven Access Shapes Dyskinesia Diagnosis and Care

North America generally benefits from established neurological services, specialized movement-disorder expertise, and growing use of digital monitoring, although access and affordability vary. Europe combines strong clinical research capacity with differences in referral pathways, reimbursement, and implementation across countries. Asia-Pacific includes advanced specialist systems alongside large populations with limited access to diagnosis and rehabilitation. Latin America faces uneven specialist distribution and infrastructure constraints, while telemedicine and multidisciplinary networks may improve reach. In the Middle East, concentrated specialist capacity coexists with access gaps between major cities and other areas. Africa continues to face substantial shortages of neurologists, diagnostic resources, medicines, and rehabilitation services, making task-sharing, primary-care education, and locally adaptable tools important priorities.

Group Insights: Policy Alignment and Health-System Capacity Drive Adoption

Within ASEAN, varied health-system maturity makes scalable screening, referral, and telehealth pathways particularly relevant. BRICS countries present significant clinical diversity, with opportunities to expand specialist networks, local research, and affordable monitoring approaches. The European Union benefits from cross-border research and regulatory coordination, while implementation remains influenced by national health systems. G7 members can contribute evidence, clinical standards, and digital-health governance. GCC countries may leverage concentrated investment and specialist infrastructure to develop integrated services, while NATO members may benefit from shared research, rehabilitation, and health-technology expertise without assuming uniform access or policy.

Country Insights: Distinct Priorities Across Major Healthcare Systems

Australia and Canada must address geographic dispersion through tele-neurology and coordinated referral models. Brazil, Mexico, India, China, Russia, and South Africa face the combined challenge of expanding specialist capacity while improving affordability and continuity of care. France, Germany, Italy, Spain, and the United Kingdom have established neurological services but continue to navigate workforce pressure, variation in access, and the integration of digital monitoring. Japan and South Korea have strong technology capabilities and aging-population considerations that support investment in validated movement assessment. The United States has extensive specialist and technology capacity, alongside persistent concerns involving coverage, fragmentation, and equitable access.

Action Priorities for Leaders: Build Validated, Connected, Patient-Centered Care

Industry leaders should prioritize clinically validated assessment tools that work across diverse populations and care settings. They should design interoperable systems linking specialist clinics, primary care, rehabilitation, pharmacies, caregivers, and patients; establish clear evidence standards for AI-enabled monitoring; and protect privacy throughout data collection and use. Partnerships with patient groups can improve outcome selection and usability. Training programs, equitable pricing and access models, post-deployment surveillance, and implementation research are also essential to ensure that innovation translates into reliable improvements in everyday care.

Research Methodology: Evidence-Led Synthesis of Dyskinesia Care Dynamics

This executive summary uses a structured qualitative approach focused on clinically established features of dyskinesia, treatment pathways, healthcare delivery, digital monitoring, and responsible artificial intelligence. Findings are organized across required regions, country groupings, and countries to identify recurring system-level opportunities and constraints. The synthesis emphasizes evidence-backed care principles and implementation considerations while excluding market estimates, market sizing, market shares, forecasts, and company-specific claims.

Conclusion: Better Monitoring and Coordinated Care Can Improve Outcomes

Dyskinesia management is moving toward more continuous assessment, coordinated multidisciplinary care, and individualized decisions. Regional and country differences mean that successful approaches must be adaptable to local workforce, infrastructure, reimbursement, and cultural conditions. Carefully validated artificial intelligence, combined with stronger referral networks and patient-centered support, can improve recognition and continuity of care when deployed with appropriate clinical governance and equity safeguards.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Dyskinesia Market, by Dyskinesia Type
7.1. Introduction
7.2. Athetosis
7.3. Chorea
7.4. Dystonia-Related Dyskinesia
7.5. Myoclonic Dyskinesia
7.6. Parkinson’s Dyskinesia
7.7. Spasmodic Torticollis
7.8. Tardive Dyskinesia
8. Dyskinesia Market, by Treatment Type
8.1. Introduction
8.2. Non-Pharmacological Approaches
8.2.1. Behavioral Therapy
8.2.2. Physical Therapy & Rehabilitation
8.3. Pharmacological Treatments
8.3.1. Anticholinergics
8.3.2. Dopamine Modulators
8.3.3. GABA Agonists
8.3.4. NMDA Receptor Antagonists
8.3.5. VMAT2 Inhibitors
8.4. Surgical Treatments
8.4.1. Ablative Surgery
8.4.2. Deep Brain Stimulation (DBS)
9. Dyskinesia Market, by Route of Administration
9.1. Introduction
9.2. Intravenous (IV) & Infusion-Based
9.3. Oral
9.4. Subcutaneous
9.5. Transdermal
10. Dyskinesia Market, by Patient Care Settings
10.1. Introduction
10.2. Home Care
10.3. Hospitals
10.4. Research Institutes
10.5. Specialty Clinics & Rehabilitation Centers
11. Dyskinesia Market, by End User
11.1. Introduction
11.2. Homecare Settings
11.3. Hospitals & Clinics
11.3.1. Inpatient Services
11.3.2. Outpatient Services
11.4. Long-Term Care Facilities
11.5. Specialty Movement Disorder Centers
12. Dyskinesia Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Dyskinesia Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Dyskinesia Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. AbbVie Inc.
16.3. Addex Therapeutics Ltd.
16.4. Bukwang Pharmaceutical Co., Ltd
16.5. Clearmind Medicine Inc.
16.6. Ipsen Pharma SAS
16.7. IRLAB Therapeutics AB
16.8. Luye Pharma Group Ltd.
16.9. Medtronic PLC
16.10. Melior Pharmaceuticals
16.11. Mitsubishi Tanabe Pharma Corporation
16.12. Motac France Sarl
16.13. Neurocrine Biosciences, Inc.
16.14. Neurolixis Inc.
16.15. PharmaTher Holdings Ltd.
16.16. Prilenia Therapeutics B.V.
16.17. ReCode Therapeutics, Inc.
16.18. Serina Therapeutics, Inc.
16.19. SOM INNOVATION BIOTECH, SA
16.20. Supernus Pharmaceuticals, Inc.
16.21. Teva Pharmaceutical Industries Ltd.
16.22. Toray Industries, Inc.
16.23. Vistagen Therapeutics, Inc.
16.24. Voyager Therapeutics, Inc.
16.25. Zydus Lifesciences Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Dyskinesia Market, Years Considered for the Study
FIGURE 2. Global Dyskinesia Market, Research Design
FIGURE 3. Global Dyskinesia Market, Research Framework
FIGURE 4. Global Dyskinesia Market, Data Triangulation
FIGURE 5. Global Dyskinesia Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Dyskinesia Market Size, by Dyskinesia Type, 2025 vs 2032 (%)
FIGURE 7. Global Dyskinesia Market Size, by Dyskinesia Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Dyskinesia Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 9. Global Dyskinesia Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Dyskinesia Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Dyskinesia Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Dyskinesia Market Size, by Patient Care Settings, 2025 vs 2032 (%)
FIGURE 13. Global Dyskinesia Market Size, by Patient Care Settings, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Dyskinesia Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Dyskinesia Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Dyskinesia Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Dyskinesia Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Dyskinesia Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Dyskinesia Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Dyskinesia Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Dyskinesia Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Dyskinesia Market Segmentation & Coverage
TABLE 2. Global Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 3. Global Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 4. Global Athetosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Athetosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Athetosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Chorea Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Chorea Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Chorea Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Dystonia-Related Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Dystonia-Related Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Dystonia-Related Dyskinesia Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Myoclonic Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Myoclonic Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Myoclonic Dyskinesia Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Parkinson’s Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Parkinson’s Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Parkinson’s Dyskinesia Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Spasmodic Torticollis Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Spasmodic Torticollis Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Spasmodic Torticollis Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Tardive Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Tardive Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Tardive Dyskinesia Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 26. Global Non-Pharmacological Approaches Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Non-Pharmacological Approaches Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Non-Pharmacological Approaches Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Behavioral Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Behavioral Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Behavioral Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Physical Therapy & Rehabilitation Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Physical Therapy & Rehabilitation Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Physical Therapy & Rehabilitation Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Pharmacological Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Pharmacological Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Pharmacological Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Anticholinergics Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Anticholinergics Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Anticholinergics Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Dopamine Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Dopamine Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Dopamine Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global GABA Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global GABA Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global GABA Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global NMDA Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global NMDA Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global NMDA Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global VMAT2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global VMAT2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global VMAT2 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Surgical Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Surgical Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Surgical Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Ablative Surgery Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Ablative Surgery Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Ablative Surgery Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Deep Brain Stimulation (DBS) Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Deep Brain Stimulation (DBS) Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Deep Brain Stimulation (DBS) Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 63. Global Intravenous (IV) & Infusion-Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Intravenous (IV) & Infusion-Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Intravenous (IV) & Infusion-Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 76. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Specialty Clinics & Rehabilitation Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Specialty Clinics & Rehabilitation Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Specialty Clinics & Rehabilitation Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Inpatient Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Inpatient Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Inpatient Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Outpatient Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Outpatient Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Outpatient Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Long-Term Care Facilities Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Long-Term Care Facilities Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Long-Term Care Facilities Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Specialty Movement Disorder Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Specialty Movement Disorder Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Specialty Movement Disorder Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 118. North America Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. North America Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 120. North America Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 121. North America Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 122. North America Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 123. North America Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 124. North America Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 125. North America Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 126. North America Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. North America Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 128. Latin America Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Latin America Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 130. Latin America Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 131. Latin America Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 132. Latin America Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 133. Latin America Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 134. Latin America Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 135. Latin America Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 136. Latin America Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. Latin America Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 138. Europe Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Europe Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 140. Europe Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 141. Europe Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 142. Europe Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 143. Europe Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 144. Europe Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 145. Europe Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 146. Europe Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. Europe Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 148. Middle East Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Middle East Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 150. Middle East Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 151. Middle East Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 152. Middle East Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 153. Middle East Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 154. Middle East Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 155. Middle East Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 156. Middle East Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Middle East Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 158. Africa Dyskinesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Africa Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 160. Africa Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 161. Africa Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 162. Africa Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 163. Africa Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 164. Africa Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 165. Africa Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 166. Africa Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Africa Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 168. Global Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. ASEAN Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. ASEAN Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 171. ASEAN Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 172. ASEAN Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 173. ASEAN Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 174. ASEAN Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 175. ASEAN Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 176. ASEAN Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 177. ASEAN Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. ASEAN Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 179. GCC Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 180. GCC Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 181. GCC Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 182. GCC Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 183. GCC Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 184. GCC Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 185. GCC Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 186. GCC Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 187. GCC Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. GCC Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 189. European Union Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. European Union Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 191. European Union Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 192. European Union Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 193. European Union Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 194. European Union Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 195. European Union Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 196. European Union Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 197. European Union Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. European Union Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 199. BRICS Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. BRICS Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 201. BRICS Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 202. BRICS Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 203. BRICS Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 204. BRICS Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 205. BRICS Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 206. BRICS Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 207. BRICS Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. BRICS Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 209. G7 Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 210. G7 Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 211. G7 Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 212. G7 Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 213. G7 Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 214. G7 Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 215. G7 Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 216. G7 Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 217. G7 Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. G7 Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 219. NATO Dyskinesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 220. NATO Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 221. NATO Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 222. NATO Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 223. NATO Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 224. NATO Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 225. NATO Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 226. NATO Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 227. NATO Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 228. NATO Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 229. Global Dyskinesia Market Size, by Country, 2017-2032 (USD Million)
TABLE 230. United States Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 231. United States Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 232. United States Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 233. United States Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 234. United States Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 235. United States Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 236. United States Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 237. United States Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 238. United States Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. United States Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 240. Canada Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 241. Canada Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 242. Canada Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 243. Canada Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 244. Canada Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 245. Canada Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 246. Canada Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 247. Canada Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 248. Canada Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. Canada Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 250. Mexico Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 251. Mexico Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 252. Mexico Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 253. Mexico Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 254. Mexico Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 255. Mexico Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 256. Mexico Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 257. Mexico Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 258. Mexico Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. Mexico Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 260. Brazil Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 261. Brazil Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 262. Brazil Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 263. Brazil Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 264. Brazil Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 265. Brazil Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 266. Brazil Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 267. Brazil Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 268. Brazil Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. Brazil Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 270. United Kingdom Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 271. United Kingdom Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 272. United Kingdom Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 273. United Kingdom Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 274. United Kingdom Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 275. United Kingdom Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 276. United Kingdom Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 277. United Kingdom Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 278. United Kingdom Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 279. United Kingdom Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 280. Germany Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 281. Germany Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 282. Germany Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 283. Germany Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 284. Germany Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 285. Germany Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 286. Germany Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 287. Germany Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 288. Germany Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. Germany Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 290. France Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 291. France Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 292. France Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 293. France Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 294. France Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 295. France Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 296. France Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 297. France Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 298. France Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 299. France Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 300. Russia Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 301. Russia Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 302. Russia Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 303. Russia Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 304. Russia Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 305. Russia Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 306. Russia Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 307. Russia Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 308. Russia Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 309. Russia Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 310. Italy Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 311. Italy Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 312. Italy Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 313. Italy Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 314. Italy Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 315. Italy Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 316. Italy Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 317. Italy Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 318. Italy Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 319. Italy Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 320. Spain Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 321. Spain Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 322. Spain Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 323. Spain Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 324. Spain Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 325. Spain Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 326. Spain Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 327. Spain Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 328. Spain Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 329. Spain Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 330. China Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 331. China Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 332. China Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 333. China Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 334. China Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 335. China Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 336. China Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 337. China Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 338. China Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 339. China Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 340. India Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 341. India Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 342. India Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 343. India Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 344. India Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 345. India Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 346. India Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 347. India Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 348. India Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 349. India Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 350. Japan Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 351. Japan Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 352. Japan Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 353. Japan Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 354. Japan Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 355. Japan Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 356. Japan Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 357. Japan Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 358. Japan Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 359. Japan Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 360. Australia Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 361. Australia Dyskinesia Market Size, by Dyskinesia Type, 2017-2032 (USD Million)
TABLE 362. Australia Dyskinesia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 363. Australia Dyskinesia Market Size, by Non-Pharmacological Approaches, 2017-2032 (USD Million)
TABLE 364. Australia Dyskinesia Market Size, by Pharmacological Treatments, 2017-2032 (USD Million)
TABLE 365. Australia Dyskinesia Market Size, by Surgical Treatments, 2017-2032 (USD Million)
TABLE 366. Australia Dyskinesia Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 367. Australia Dyskinesia Market Size, by Patient Care Settings, 2017-2032 (USD Million)
TABLE 368. Australia Dyskinesia Market Size, by End User, 2017-2032 (USD Million)
TABLE 369. Australia Dyskinesia Market Size, by Hospitals & Clinics, 2017-2032 (USD Million)
TABLE 370. South Korea Dyskinesia Market Size, 2017-2032 (USD Million)
TABLE 371. South Korea Dyskinesia Market Size, b

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Bukwang Pharmaceutical Co., Ltd
  • Clearmind Medicine Inc.
  • Ipsen Pharma SAS
  • IRLAB Therapeutics AB
  • Luye Pharma Group Ltd.
  • Medtronic PLC
  • Melior Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Motac France Sarl
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • PharmaTher Holdings Ltd.
  • Prilenia Therapeutics B.V.
  • ReCode Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SOM INNOVATION BIOTECH, SA
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Vistagen Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Tardive Dyskinesia Therapeutics - Global Strategic Business Report - Product Image

Tardive Dyskinesia Therapeutics - Global Strategic Business Report

  • Report
  • 240 Pages
  • Global
From
Tardive Dyskinesia Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Disorder (Bradykinesia, Hyperkinesia), Drug Class, Route of Administration, Distribution Channel - Product Image

Tardive Dyskinesia Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Disorder (Bradykinesia, Hyperkinesia), Drug Class, Route of Administration, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Tardive Dyskinesia Therapeutics Market Report 2026 - Product Image

Tardive Dyskinesia Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Tardive Dyskinesia Treatment Market Report 2026 - Product Image

Tardive Dyskinesia Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Global Tardive Dyskinesia Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Global Tardive Dyskinesia Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 117 Pages
  • Global
From

About the Dyskinesia Market

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression. The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms. Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.